Merck said on June 22 that its investigational therapy met the primary endpoint in a late-stage trial for a form of inflammatory bowel disease. The result represents a key clinical milestone for the drug. Detailed efficacy and safety data have not yet been released, and Merck has not announced regulatory plans. Stakeholders await full trial results to assess the treatment's potential impact.
Merck's Investigational IBD Therapy Meets Primary Endpoint in Late-Stage Trial
The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid
June 22 (Reuters) - Merck announced on Monday that an investigational therapy met the primary endpoint in a late-stage clinical trial evaluating treatment for patients with a form of inflammatory bowel disease (IBD).
The company said the study achieved its main objective, marking an important milestone in the drug's clinical development. Merck did not disclose detailed efficacy or safety results, nor did it outline next-step regulatory plans.
Key Details
- Trial Phase: Late-stage (pivotal) clinical trial.
- Outcome: Primary endpoint met; primary efficacy objective achieved.
- Disease Area: A form of inflammatory bowel disease (company did not specify subtype).
- Data Availability: Full efficacy and safety data have not yet been released.
- Regulatory Plans: No regulatory submission timeline announced.
Merck's announcement signals progress but leaves important questions unanswered until the company publishes detailed trial data and outlines regulatory steps. Investors, clinicians and patient communities will likely await more information on the magnitude of benefit, safety profile and next steps toward approval.
Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo
Help us improve.
